Class Action Notice for Soleno Therapeutics Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy SLNO?
Source: PRnewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Soleno Therapeutics (NASDAQ:SLNO) common stock between March 26, 2025, and November 4, 2025, that they must apply to be lead plaintiff by May 5, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Soleno concealed significant safety concerns related to its DCCR drug during clinical trials, including issues of fluid retention in participants, which resulted in materially greater safety risks and diminished commercial viability for investors.
- Law Firm Advantages: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its successful track record and extensive experience, prompting investors to carefully select qualified legal counsel.
- Investor Rights Protection: Until the class action is certified, investors can choose to retain their own legal counsel or opt-out, ensuring that their potential recovery in the future is not contingent upon serving as lead plaintiff, thereby safeguarding their rights.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLNO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLNO
Wall Street analysts forecast SLNO stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 31.860
Low
75.00
Averages
110.50
High
125.00
Current: 31.860
Low
75.00
Averages
110.50
High
125.00
About SLNO
Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Class Action Notice for Soleno Therapeutics Investors
- Class Action Timeline: Investors who purchased common stock of Soleno Therapeutics (NASDAQ: SLNO) between March 26, 2025, and November 4, 2025, should note that the deadline to apply as lead plaintiff is May 5, 2026, and failure to act may result in loss of compensation rights.
- Lawsuit Background: The lawsuit alleges that Soleno concealed significant safety issues related to its DCCR drug during clinical trials, including serious side effects like fluid retention, leading to investor losses when the true information was revealed, thereby impacting the company's reputation and market trust.
- Legal Counsel Selection: Investors are advised to choose legal counsel with a proven track record; Rosen Law Firm has excelled in securities class actions, having been ranked No. 1 by ISS in 2017, showcasing its expertise and resource advantages in this field.
- Potential Compensation Mechanism: Investors participating in the class action can receive compensation without any upfront costs through a contingency fee arrangement, providing a risk-free avenue for affected investors to seek redress and enhancing their confidence in the process.
See More
Faruqi & Faruqi Investigates Soleno Investor Losses
- Legal Investigation Initiated: Faruq & Faruqi, LLP is investigating Soleno Therapeutics, focusing on investors who purchased or acquired securities between March 26, 2025, and November 4, 2025, to assess potential legal claims.
- Investor Rights Reminder: The firm reminds investors that May 5, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of timely action to protect their rights.
- Contact Information Provided: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing phone numbers for discussions on legal options, demonstrating a commitment to client support.
- Market Reaction Anticipation: The initiation of the legal investigation may negatively impact Soleno's stock price, prompting investors to closely monitor developments to adjust their investment strategies accordingly.
See More
Soleno Therapeutics Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: Soleno Therapeutics (NASDAQ: SLNO) is facing a securities fraud class action lawsuit for the period between March 26, 2025, and November 4, 2025, with investors having until May 5, 2026, to seek lead plaintiff status, indicating significant legal risks that could impact stock price and market trust.
- Key Allegations: The lawsuit alleges that the company made materially false statements and omissions regarding its DCCR drug's Phase 3 clinical trial, particularly failing to disclose safety concerns, which could lead to severe misjudgments about the company's future business prospects by investors.
- Stock Price Impact: Following the financial results announcement on November 4, 2025, Soleno's stock price plummeted over 26% due to the revelation of negative information related to DCCR, reflecting market concerns over the company's operational transparency and potential financial losses.
- Investor Action: Affected investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation, highlighting the potential financial liabilities the company may face in the legal proceedings and the implications for investors.
See More
Securities Class Action Filed Against Soleno Therapeutics Amid Disappointing Drug Report
- Lawsuit Background: Soleno Therapeutics is facing a securities class action lawsuit following a disappointing report on its DCCR drug (trademarked as VYKAT™ XR) released on November 5, 2025, representing investors who purchased shares between March 26 and November 4, 2025, highlighting significant investor dissatisfaction with the company's transparency.
- Stock Price Plunge: The report triggered a 26% drop in Soleno's stock price on the same day, reflecting severe market concerns regarding the safety and efficacy of its drug, which directly impacted investor confidence and the company's market capitalization.
- Safety Concerns: The lawsuit alleges that Soleno concealed significant safety risks associated with DCCR during clinical trials, particularly issues related to fluid retention, leading to a major misunderstanding of the drug's commercial viability and potentially affecting future sales and market acceptance.
- Market Reaction: On August 15, 2025, activist short seller Scorpion Capital raised questions about Soleno's disclosures, noting a surge in reports of children hospitalized after using the drug, further exacerbating the crisis of trust in Soleno and causing its stock price to fall nearly 40% since that date.
See More
Soleno Therapeutics Shareholder Alert Issued
- Lawsuit Notification: The Gross Law Firm has issued a notice to shareholders of Soleno Therapeutics, encouraging those who purchased SLNO shares between March 26, 2025, and November 4, 2025, to contact the firm regarding potential lead plaintiff status for recovery participation.
- Safety Concerns Allegations: The complaint alleges that Soleno systematically downplayed and concealed significant safety concerns related to its DCCR product during Phase 3 clinical trials, including issues of excess fluid retention in participants, which has severely impacted the drug's commercial viability.
- Increased Risk Potential: Due to undisclosed safety risks, the administration of DCCR for treating individuals with PWS may pose materially greater safety risks than disclosed, potentially leading to higher patient discontinuation rates, prescriber reluctance, and adverse regulatory actions that could harm the company's reputation.
- Shareholder Action Deadline: Shareholders must register for this class action by May 5, 2026, to participate in any recovery; those who do not register will be unable to claim damages, and registered shareholders will receive updates on the case's progress.
See More
Soleno Faces Class Action for Misleading Investors
- Lawsuit Background: Soleno Therapeutics is facing a securities class action lawsuit for allegedly misleading investors regarding the safety and efficacy of its DCCR drug, covering the period from March 26 to November 4, 2025, indicating significant information concealment during the drug's launch.
- Stock Price Plunge: Following the release of unfavorable news on November 5, 2025, Soleno's stock price plummeted by 26%, reflecting strong market concerns about the company's future and severely undermining investor confidence.
- Safety Risks Exposed: The lawsuit alleges that Soleno concealed significant safety risks associated with DCCR, including issues related to fluid retention in clinical trials, which further diminishes the drug's commercial viability and raises the possibility of market withdrawal.
- Ongoing Investigation: Hagens Berman is investigating whether Soleno violated federal securities laws and is encouraging affected investors to come forward, highlighting ongoing concerns regarding corporate governance and transparency.
See More
Class Action Notice for Soleno Therapeutics Investors
- Class Action Timeline: Investors who purchased common stock of Soleno Therapeutics (NASDAQ: SLNO) between March 26, 2025, and November 4, 2025, should note that the deadline to apply as lead plaintiff is May 5, 2026, and failure to act may result in loss of compensation rights.
- Lawsuit Background: The lawsuit alleges that Soleno concealed significant safety issues related to its DCCR drug during clinical trials, including serious side effects like fluid retention, leading to investor losses when the true information was revealed, thereby impacting the company's reputation and market trust.
- Legal Counsel Selection: Investors are advised to choose legal counsel with a proven track record; Rosen Law Firm has excelled in securities class actions, having been ranked No. 1 by ISS in 2017, showcasing its expertise and resource advantages in this field.
- Potential Compensation Mechanism: Investors participating in the class action can receive compensation without any upfront costs through a contingency fee arrangement, providing a risk-free avenue for affected investors to seek redress and enhancing their confidence in the process.
See More
Faruqi & Faruqi Investigates Soleno Investor Losses
- Legal Investigation Initiated: Faruq & Faruqi, LLP is investigating Soleno Therapeutics, focusing on investors who purchased or acquired securities between March 26, 2025, and November 4, 2025, to assess potential legal claims.
- Investor Rights Reminder: The firm reminds investors that May 5, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of timely action to protect their rights.
- Contact Information Provided: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing phone numbers for discussions on legal options, demonstrating a commitment to client support.
- Market Reaction Anticipation: The initiation of the legal investigation may negatively impact Soleno's stock price, prompting investors to closely monitor developments to adjust their investment strategies accordingly.
See More
Soleno Therapeutics Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: Soleno Therapeutics (NASDAQ: SLNO) is facing a securities fraud class action lawsuit for the period between March 26, 2025, and November 4, 2025, with investors having until May 5, 2026, to seek lead plaintiff status, indicating significant legal risks that could impact stock price and market trust.
- Key Allegations: The lawsuit alleges that the company made materially false statements and omissions regarding its DCCR drug's Phase 3 clinical trial, particularly failing to disclose safety concerns, which could lead to severe misjudgments about the company's future business prospects by investors.
- Stock Price Impact: Following the financial results announcement on November 4, 2025, Soleno's stock price plummeted over 26% due to the revelation of negative information related to DCCR, reflecting market concerns over the company's operational transparency and potential financial losses.
- Investor Action: Affected investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation, highlighting the potential financial liabilities the company may face in the legal proceedings and the implications for investors.
See More
Securities Class Action Filed Against Soleno Therapeutics Amid Disappointing Drug Report
- Lawsuit Background: Soleno Therapeutics is facing a securities class action lawsuit following a disappointing report on its DCCR drug (trademarked as VYKAT™ XR) released on November 5, 2025, representing investors who purchased shares between March 26 and November 4, 2025, highlighting significant investor dissatisfaction with the company's transparency.
- Stock Price Plunge: The report triggered a 26% drop in Soleno's stock price on the same day, reflecting severe market concerns regarding the safety and efficacy of its drug, which directly impacted investor confidence and the company's market capitalization.
- Safety Concerns: The lawsuit alleges that Soleno concealed significant safety risks associated with DCCR during clinical trials, particularly issues related to fluid retention, leading to a major misunderstanding of the drug's commercial viability and potentially affecting future sales and market acceptance.
- Market Reaction: On August 15, 2025, activist short seller Scorpion Capital raised questions about Soleno's disclosures, noting a surge in reports of children hospitalized after using the drug, further exacerbating the crisis of trust in Soleno and causing its stock price to fall nearly 40% since that date.
See More
Soleno Therapeutics Shareholder Alert Issued
- Lawsuit Notification: The Gross Law Firm has issued a notice to shareholders of Soleno Therapeutics, encouraging those who purchased SLNO shares between March 26, 2025, and November 4, 2025, to contact the firm regarding potential lead plaintiff status for recovery participation.
- Safety Concerns Allegations: The complaint alleges that Soleno systematically downplayed and concealed significant safety concerns related to its DCCR product during Phase 3 clinical trials, including issues of excess fluid retention in participants, which has severely impacted the drug's commercial viability.
- Increased Risk Potential: Due to undisclosed safety risks, the administration of DCCR for treating individuals with PWS may pose materially greater safety risks than disclosed, potentially leading to higher patient discontinuation rates, prescriber reluctance, and adverse regulatory actions that could harm the company's reputation.
- Shareholder Action Deadline: Shareholders must register for this class action by May 5, 2026, to participate in any recovery; those who do not register will be unable to claim damages, and registered shareholders will receive updates on the case's progress.
See More
Soleno Faces Class Action for Misleading Investors
- Lawsuit Background: Soleno Therapeutics is facing a securities class action lawsuit for allegedly misleading investors regarding the safety and efficacy of its DCCR drug, covering the period from March 26 to November 4, 2025, indicating significant information concealment during the drug's launch.
- Stock Price Plunge: Following the release of unfavorable news on November 5, 2025, Soleno's stock price plummeted by 26%, reflecting strong market concerns about the company's future and severely undermining investor confidence.
- Safety Risks Exposed: The lawsuit alleges that Soleno concealed significant safety risks associated with DCCR, including issues related to fluid retention in clinical trials, which further diminishes the drug's commercial viability and raises the possibility of market withdrawal.
- Ongoing Investigation: Hagens Berman is investigating whether Soleno violated federal securities laws and is encouraging affected investors to come forward, highlighting ongoing concerns regarding corporate governance and transparency.
See More
